Colitis, Ulcerative Clinical Trial
Official title:
Development of Combined Nutritional Therapies for the Treatment of Ulcerative Colitis Through the Increase of the Biodiversity of the Microbiota.
Ulcerative colitis (UC) is an entity of complex etiology where environmental, genetic and intestinal microflora-related factors trigger and perpetuate a chronic inflammation of the gastrointestinal tract. It is suspected that an alteration in primary intestinal microbial colonization (dysbiosis) could trigger, or at least contribute to, said oversized immune response. The hypothesis is that the administration of a series of fibers, could improve the bacterial diversity and repair the dysbiosis that has been seen in patients affected by ulcerative colitis, improving the clinical evolution of it. The primary objective of the present study is to know the impact on the microbiota of patients with UC in remission derived from the administration of dietary fibers. The RETOS study is a pilot project in which a population of patients with UC is tested for the effect on the composition of the microbiota that would have the administration of various combinations of fibers, in addition to the tolerability and acceptance by the patient. The clinical applicability derived from this intervention would be to improve the diversity of intestinal flora of patients with ulcerative colitis.
The Phase 1 study is a pilot project in which a population of patients with UC is tested for
the effect on the composition of the microbiota that would have the administration of various
combinations of fibers, in addition to the tolerability and acceptance by the patient. The
study will include two groups of 20 patients each. One of the groups will receive 6 grams of
fiber a day in a single shot with the main meal (group 1) and the other group will receive 12
grams of fiber a day divided into two meals with the main meals (group 2). Two different
combinations of fibers (formula A and B) will be tested with the following administration
pattern for both groups.
Description of the administration pattern Week 1: Formula A Week 2: Formula A Week 3: Formula
B Week 4: Formula B
A second sequential cycle similar to the first one (4 weeks with the same administration
pattern) will be repeated in order to confirm the reproducibility of the findings.
The two formulas contain fibers known and commonly used in human nutrition, which were
previously tested in in vitro models with human faeces and their ability to promote the
growth of butyrate-producing bacterial species that are deficient in patients with colitis
was proven ulcerative (Faecalibacterium prausnitzii and Roseburia hominis). The fibers are
presented in aluminum envelopes to dissolve in a glass of water, juice, infusion or cold
cream (max 37 ° C).
In addition, formulas A and B for group 1 (a single intake per day) include the mixture of
probiotics i3.1 in quantity per envelope of 3e + 9 colony-forming units, which contains:
Pediococcus acidilactici CECT 7483, Lactobacillus plantarum CECT 7484 and Lactobacillus
plantarum CECT 7485 in a 1: 1: 1 ratio. Formulas A and B for group 2 (two intakes per day)
include the probiotic i3.1 in quantity per envelope of 1.5e + 09 colony-forming units.
In the two groups, the first week the patients will receive half of the dose with the aim of
facilitating the adaptation in those people who usually do not consume fiber. The usual diet,
tolerability and patient satisfaction will be controlled through biweekly predefined
questionnaires.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04989907 -
A Study in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) Receiving Vedolizumab in Real-World Practice in Switzerland
|
||
Completed |
NCT03494764 -
Hyperbaric Oxygen Therapy for Ulcerative Colitis Flares
|
Phase 2 | |
Recruiting |
NCT03937609 -
TITRATE (inducTIon for acuTe ulceRATivE Colitis)
|
Phase 4 | |
Completed |
NCT00503243 -
Safety and Efficacy of SPD476 (Mesalazine) Given Twice Daily (2.4 g/Day) vs SPD476 Given as a Single Dose (4.8 g/Day) in Subjects With Acute Mild to Moderate Ulcerative Colitis
|
Phase 3 | |
Completed |
NCT03606499 -
Real-world Effectiveness of Ustekinumab in Participants Suffering From Inflammatory Bowel Disease (Crohn's Disease or Ulcerative Colitis) With Extra-intestinal Manifestations or Immune-mediated Inflammatory Diseases
|
||
Completed |
NCT02537210 -
Aminosalicylic Acid Withdrawal Study in Long Standing Inactive Ulcerative Colitis
|
N/A | |
Active, not recruiting |
NCT02316678 -
Patient Attitudes and Preferences for Outcomes of Inflammatory Bowel Disease Therapeutics
|
N/A | |
Completed |
NCT00488631 -
An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis
|
Phase 3 | |
Completed |
NCT00928681 -
A Study To Investigate The Safety And Efficacy Properties Of PF-00547659 In Patients With Active Ulcerative Colitis
|
Phase 1 | |
Recruiting |
NCT05242484 -
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
|
Phase 2 | |
Completed |
NCT01036022 -
Effect of GSK1399686 in Patients With Mild to Moderately Active Ulcerative Colitis
|
Phase 2 | |
Recruiting |
NCT03841045 -
Unraveling a Potential Connection Between Bilirubin Metabolism, Gut Microbiota and Inflammatory Bowel Diseases
|
||
Active, not recruiting |
NCT05528510 -
A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis
|
Phase 3 | |
Completed |
NCT02825914 -
CAsein GLycomacropeptide in Ulcerative Colitis - Anti-Inflammatory and Microbiome Modulating Effects (CAGLUCIM)
|
N/A | |
Recruiting |
NCT06049017 -
A Study of JNJ-77242113 in Participants With Moderately to Severely Active Ulcerative Colitis
|
Phase 2 | |
Completed |
NCT04567628 -
Study of Relationship Between Vedolizumab Therapeutic Drug Monitoring, Biomarkers of Inflammation and Clinical Outcomes
|
||
Withdrawn |
NCT05999708 -
A First Time in Human Study to Evaluate the Safety and Tolerability of GSK4381406 in Healthy Participants
|
Phase 1 | |
Recruiting |
NCT05611671 -
A Study to Evaluate MORF-057 in Adults With Moderately to Severely Active UC
|
Phase 2 | |
Active, not recruiting |
NCT03596645 -
A Study to Assess the Efficacy and Safety of Golimumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis
|
Phase 3 | |
Completed |
NCT03648541 -
BI 655130 Long-term Treatment in Patients With moderate-to Severe Ulcerative Colitis
|
Phase 2 |